[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100563903":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":36,"studyPopulation":25,"armGroups":37,"interventions":56,"overallOfficials":69,"centralContacts":74,"locations":25,"responsibleParty":83,"collaborators":86,"id":90,"slug":25,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":25,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":97,"minAge":98,"maxAge":99,"enrollmentInfo":100,"targetDuration":25,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":111,"whyStopped":25,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":25},{"fullName":5,"class":6},"Khon Kaen University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":25},[9,13],{"measure":10,"description":11,"timeFrame":12},"Reduction of ulcer size after using product","Reduction of ulcer size will be evaluated by measuring the diameter of ulcers size using a periodontal probe and photograph on the first day and each follow up visit.","Base line, day4, day7, day10 and day 14",{"measure":14,"description":15,"timeFrame":12},"Pain score","The pain score will be assessed by using a visual analogue scale (VAS) which is a 10-cm line on that was labeled from \\"no pain\\"(0) to \\"worst pain\\" (10).The pain level will be recorded on the first day. The participants will then reassess their pain score again after receiving the intervention, which will be evaluated at each follow up visit.",[17,21],{"measure":18,"description":19,"timeFrame":20},"Satisfaction score","Participants\\' satisfaction after using product will be assessed using a visual analogue scale (VAS) which is a 10-cm line on that was labeled from \\"unsatisfied\\" (0) to \\"most satisfied\\" (10). Satisfaction will be evaluated on the last day of follow-up.","Day 14",{"measure":22,"description":23,"timeFrame":24},"Quality of life score","Oral health impact on quality of life will be evaluated using the Thai version of the Oral Health Impact Profile-14 (OHIP-14). The survey classified into 7 dimensions with 2 items per dimension included functional limitation, painful, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Participants must choose the answer based on the frequency of problem occurrence. The frequency level is divided into 5 level: never= 0 point, rarely = 1 point, sometimes = 2 points, often = 3 points, always = 4 points. Total scores in each person range are between 0 to 56 points.The quality of life will be survey on the first and the last day of follow-up.","base line and day 14",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":29,"primaryPurpose":30,"observationalModel":25,"timePerspective":25,"maskingInfo":31},"RANDOMIZED","PARALLEL","group 1: mucoadhesive film with Acmella oleracea extract, group 2: 0.1% triamcinolone acetonide, and group 3: mucoadhesive film without Acmella oleracea extract.","TREATMENT",{"masking":32,"maskingDescription":33,"whoMasked":34},"SINGLE","Outcome assessor will not know which treatment each participant will receive (single blinding). Participants will know the type of treatment they received.",[35],"OUTCOMES_ASSESSOR","Participants who consent and meet the inclusion criteria will be allocated into 3 groups using block randomization: group 1: mucoadhesive film with Acmella oleracea extract, group 2: 0.1% triamcinolone acetonide, and group 3: mucoadhesive film without Acmella oleracea extract.",[38,44,50],{"label":39,"type":40,"description":41,"interventionNames":42},"mucoadhesive film with Acmella oleracea extract","EXPERIMENTAL","Participants received mucoadhesive film with Acmella oleracea extract.",[43],"Other: mucoadhesive film with Acmella oleracea extract",{"label":45,"type":46,"description":47,"interventionNames":48},"Triamcinolone acetonide","ACTIVE_COMPARATOR","Participants received 0.1% Triamcinolone acetonide.",[49],"Drug: Triamcinolone Acetonide 0.1% Oromucosal Paste",{"label":51,"type":52,"description":53,"interventionNames":54},"mucoadhesive film without Acmella oleracea extract","PLACEBO_COMPARATOR","Participants received mucoadhesive film without Acmella oleracea extract.",[55],"Other: mucoadhesive film without Acmella oleracea extract",[57,60,67],{"type":6,"name":39,"description":58,"armGroupLabels":59,"otherNames":25},"Apply 1 patch on ulcer 3 times per day (after meals)",[39],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":65},"DRUG","Triamcinolone Acetonide 0.1% Oromucosal Paste","Apply ¼ inch on ulcer 3 times per day (after meals)",[45],[66],"Trinolone oral paste",{"type":6,"name":51,"description":58,"armGroupLabels":68,"otherNames":25},[51],[70],{"name":71,"affiliation":72,"role":73},"Kemporn Kitsahawong, Ph.D","KhonKaen university","PRINCIPAL_INVESTIGATOR",[75,79],{"name":71,"role":76,"phone":77,"phoneExt":25,"email":78},"CONTACT","(+66)91-4442699","kkempo@kku.ac.th",{"name":80,"role":76,"phone":81,"phoneExt":25,"email":82},"Porntip Phajongviriyatorn, MsC.","(+66)86-7165260","ppornt@kku.ac.th",{"type":73,"investigatorFullName":84,"investigatorTitle":85,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Kemporn Kitsahawong","Principle investigator",[87],{"name":88,"class":89},"National Institute of Dental and Craniofacial Research (NIDCR)","NIH","100563903",false,"NCT06622213","Mucoadhesive Film With\u002Fwithout Acmella Oleracea & Triamcinolone Acetonide for Aphthous Ulcers","Comparison of the Efficacy of Mucoadhesive Film with and Without Acmella Oleracea Extract and 0.1% Triamcinolone Acetonide for Treatment of Aphthous Ulcers: a Randomized Control Trial","Inclusion Criteria:\n\n1. Healthy participants aged 18-50 years without any underlying diseases.\n2. Participants are voluntary and have signed the informed consent.\n3. Participants are literate.\n4. Participants can follow the treatment guidelines and follow up.\n5. Participants have one untreated oral ulcer lesion.\n\n   * An ulcer has occurred within 48 hours.\n   * The ulcer size is less than 10 mm.\n   * The ulcer is clearly visible and located on non-keratinized oral mucosa such as buccal mucosa, labial mucosa, alveolar mucosa, or buccal vestibule.\n   * The ulcer must be painful.\n6. If an ulcer is caused by a denture or orthodontic appliance, the cause must be eliminated before participation.\n7. Participants must not be currently participating in any other clinical studies about oral ulcer\n\nExclusion Criteria:\n\n1. Participants with allergies to herbal extracts, Acmella oleracea, or steroids.\n2. Participants with chronic underlying diseases.\n3. Participants with underlying diseases that may affect wound healing.\n4. Participants receiving anti-analgesic drug, systemic steroids, antibiotics, hormones, NSAIDS, or any drugs that affect the oral mucosa.\n5. Oral ulcer lesion larger than 10 mm or lesions resembling herpetic form of aphthous ulcers.\n6. Oral ulcers are caused by infection or associated with systemic diseases.\n7. Participants with poor oral hygiene requiring emergency treatment.\n8. Participants who smoke or consume alcohol regularly.\n9. Participants who are pregnant, breastfeeding, or planning to become pregnant during the study period.",true,"ALL","18 Years","50 Years",{"count":101,"type":102},72,"ESTIMATED","INTERVENTIONAL",[105],"PHASE2","The purpose of this study is to evaluate the effectiveness of mucoadhesive film with or without Acmella oleracea extract compared to standard treatment by using 0.1% triamcinolone acetonide in pain relief, promoting wound healing, healing time and satisfaction in 3 aspects included taste, product used and quality of life after using the product.",[108],"Aphthous Stomatitis",[110],"Oral ulcer","NOT_YET_RECRUITING","2024-09-30",{"date":114,"type":115},"2024-10-02","ACTUAL",{"date":117,"type":102},"2024-10-15",{"date":119,"type":102},"2026-05",{"name":5,"class":6}]